PROTEINQURE
9.7.2020 10:02:12 CEST | Business Wire | Press release
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics.
Peptide therapeutics have unique properties that make them highly effective against some disease targets outside the scope of traditional small molecule and antibody modalities. However, due to the number of peptide variations, very few of these potential therapeutics have been studied. Integrating high-accuracy biophysical models and machine learning, it is possible to explore this vast therapeutic space and design peptide libraries with broad applicability in drug discovery.
The collaboration will leverage ProteinQure's expertise in computational methods and structure-based drug design. AstraZeneca will conduct experimental validation, drawing on the company’s extensive expertise in biologics.
"We are excited to collaborate with AstraZeneca to demonstrate the application of our technology on a large scale. By combining ProteinQure's proprietary computational tools with AstraZeneca’s ability to refine and validate millions of therapeutic candidates in high-throughput, we can rapidly determine therapeutic leads outside the scope of conventional synthetic antibody libraries. State-of-the-art computational tools have not been fully explored in biologics R&D and we are excited to partner with AstraZeneca with the aim of discovering novel therapeutic leads for some of the most challenging drug targets faced by the industry," said Chris Ing, CSO, ProteinQure.
"The combination of designed peptide libraries, based on ProteinQure’s computational methods, with our advanced capabilities in display technologies will help us harness the potential of this therapeutic class. AstraZeneca continues to collaborate with cutting-edge companies in our ambition to discover novel treatments and increase the speed at which we can bring treatments to patients," said Tristan Vaughan, Vice President Antibody Discovery & Protein Engineering, R&D, AstraZeneca.
About ProteinQure Inc.
ProteinQure is a computational drug discovery platform for protein-based pharmaceuticals. Their platform combines quantum computing, machine learning and molecular dynamics simulations to help refine and optimize protein therapeutics. These techniques are less reliant on data than other computational approaches and have the potential to explore new therapeutic space. ProteinQure collaborates with its partners to help design the drugs of tomorrow. ProteinQure is headquartered in Toronto, Canada. For more information please visit www.proteinqure.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005086/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports Full Year and Fourth Quarter 2025 Results12.2.2026 07:01:00 CET | Press release
Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/ Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 “Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer environment. We exit 2025 with improved momentum and enter 2026 well positioned to engage consumers with our megabrands and an unparalleled lineup of mega platforms. Thank you to our colleagues for their ongoing commitment, hard work and passion for our business.” – Michel Doukeris, CEO, AB InBev Revenue 4Q +
Bardasz Forms Strategic Digital Alliance with GEOLOG to Accelerate Global RTOC Delivery and Digital Well Construction Solutions12.2.2026 07:00:00 CET | Press release
HighlightsBardasz and GEOLOG form an alliance to strengthen delivery of end-to-end RTOC solutions for drilling optimization and NPT mitigation.Alliance combines Bardasz’s leadership in WITSML and ETP transmission, high-speed real-time data aggregation, and Super Store technology with GEOLOG’s global operational scale and local technical workforce.As part of the alliance, GEOLOG has made a minority investment in Bardasz, providing financial flexibility to accelerate Bardasz’s product roadmap and global expansion. Bardasz Group LLC (“Bardasz”), a provider of real-time, decision-ready intelligence for well construction—including drilling, completions, and well interventions—today announced a strategic digital alliance with GEOLOG International B.V. (“GEOLOG”), a global formation evaluation, drilling, and geochemistry services provider supporting subsurface projects in more than 40 countries. The alliance is designed to accelerate Bardasz’s global growth and enhance customer delivery by le
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties12.2.2026 07:00:00 CET | Press release
Galderma unveils We Are All Sculptra, a global campaign capturing the clinical performance of Sculptra® across nine diverse patient profiles and journeys, over two years1 Backed by over 25 years of clinical use, Sculptra continues to prove its versatility as a regenerative treatment that works across all three layers of the skin2-6 The campaign captures the patients’ clinical and emotional experiences – including before & after treatment imagery – highlighting Sculptra’s adaptability and reinforcing its role in tailored, science-backed regenerative aesthetic care1 Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and dem
Lenovo Group: Third Quarter Financial Results 2025/2612.2.2026 05:13:00 CET | Press release
Lenovo delivers exceptional quarter, marks era of accelerated AI-driven growth and profitability Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported results for the third quarter of fiscal year 2025/26, a quarter that delivered record revenues, accelerated profitability, and continued AI revenue expansion. During the quarter, overall group revenue reached an all-time fiscal quarter high of US$22.2 billion, up 18% year-on-year, with revenue from all business groups growing double-digit year-on-year. Excluding non-operating non-cash items and one-time gains and charges in Q3 FY24/25 and Q3 FY25/26, adjusted net income (profit attributable to equity holders – non-HKFRS)[1] increased by 36% year-on-year to US$589 million, with adjusted net income margin[1] expanding to 2.7%. The results demonstrate the Group’s ability to deliver on its promise of double-digit growth and sustained profitability, while proving its ability to manage throu
IFF Reports Fourth Quarter and Full Year 2025 Results11.2.2026 22:36:00 CET | Press release
Delivered solid top and bottom-line performance & advanced strategic priorities in 2025Launched sale process for the Food Ingredients segmentContinuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Management Commentary “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.” “We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom